Resources

Healthcare Professionals Resources

Datasheet

ANKTIVA: How to Order

A step-by-step guide on how to order ANKTIVA, including product codes

Download PDF

Datasheet

Preparation, Administration, and Storage

A summary of storage, preparation and administration, information for ANKTIVA.

Download PDF

Datasheet

ANKTIVA: Mechanism of Action

A description of how BCG and ANKTIVA work together in NMIBC CIS

Download PDF

Datasheet

ANKTIVA: Efficacy & Safety

A clinical resource highlighting key efficacy and safety information about ANKTIVA  (nogapendekin alfa inbakicept-pmln)

Download PDF

Video

Physicians’ Journey

Listen to the physicians’ journey with their patients using ANKTIVA.

Watch Video

Patient Resources

Datasheet

Future Oncology

A plain language review of the published findings on the Phase 1b BCG-naïve and Phase 2/3  BCG-unresponsive studies (QUILT 3.032).

Download PDF

Datasheet

Getting Started with ANKTIVA for Patients

A patient-friendly overview of how ANKTIVA+BCG work as well as what patients  should expect before and after treatment.

Download PDF

Indication and Important Safety Information

INDICATION AND USAGE

ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

WARNINGS AND PRECAUTIONS

Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after a second induction course of ANKTIVA with BCG, reconsider cystectomy.

DOSAGE AND ADMINISTRATION

For lntravesical Use Only. Do not administer by subcutaneous or intravenous routes. Instill intravesically only after dilution. Total time from vial puncture to the completion of the intravesical instillation should not exceed 2 hours.

USE IN SPECIFIC POPULATIONS

Pregnancy: May cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.

ADVERSE REACTIONS

The most common (≥15%) adverse reactions, including laboratory test abnormalities, are increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills and pyrexia.

For more information about ANKTIVA, please see the Full Prescribing Information at www.anktiva.com.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatchor call 1-800-332-1088. You may also contact lmmunityBio at 1-877-ANKTIVA (1-877-265-8482)

ANKTIVA is a Novel Treatment for NMIBC CIS Patients Unresponsive to BCG

For more information, please call 1-877-ANKTIVA